143 related articles for article (PubMed ID: 23520767)
21. Allosteric binding sites at the receptor-lipid bilayer interface: novel targets for GPCR drug discovery.
Wang Y; Yu Z; Xiao W; Lu S; Zhang J
Drug Discov Today; 2021 Mar; 26(3):690-703. PubMed ID: 33301977
[TBL] [Abstract][Full Text] [Related]
22. The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors.
Valant C; Robert Lane J; Sexton PM; Christopoulos A
Annu Rev Pharmacol Toxicol; 2012; 52():153-78. PubMed ID: 21910627
[TBL] [Abstract][Full Text] [Related]
23. PAM-Antagonists: A Better Way to Block Pathological Receptor Signaling?
Kenakin T; Strachan RT
Trends Pharmacol Sci; 2018 Aug; 39(8):748-765. PubMed ID: 29885909
[TBL] [Abstract][Full Text] [Related]
24. Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65.
Huang XP; Karpiak J; Kroeze WK; Zhu H; Chen X; Moy SS; Saddoris KA; Nikolova VD; Farrell MS; Wang S; Mangano TJ; Deshpande DA; Jiang A; Penn RB; Jin J; Koller BH; Kenakin T; Shoichet BK; Roth BL
Nature; 2015 Nov; 527(7579):477-83. PubMed ID: 26550826
[TBL] [Abstract][Full Text] [Related]
25. G protein-coupled receptor dimers: functional consequences, disease states and drug targets.
Dalrymple MB; Pfleger KD; Eidne KA
Pharmacol Ther; 2008 Jun; 118(3):359-71. PubMed ID: 18486226
[TBL] [Abstract][Full Text] [Related]
26. Allosteric modulation of G protein-coupled receptors: perspectives and recent developments.
Soudijn W; Van Wijngaarden I; IJzerman AP
Drug Discov Today; 2004 Sep; 9(17):752-8. PubMed ID: 15450241
[TBL] [Abstract][Full Text] [Related]
27. Emerging opportunities for allosteric modulation of G-protein coupled receptors.
Wang CI; Lewis RJ
Biochem Pharmacol; 2013 Jan; 85(2):153-62. PubMed ID: 22975406
[TBL] [Abstract][Full Text] [Related]
28. Allosteric properties of G protein-coupled receptor oligomers.
Springael JY; Urizar E; Costagliola S; Vassart G; Parmentier M
Pharmacol Ther; 2007 Sep; 115(3):410-8. PubMed ID: 17655934
[TBL] [Abstract][Full Text] [Related]
29. Functional selectivity in GPCR signaling: understanding the full spectrum of receptor conformations.
Goupil E; Laporte SA; Hébert TE
Mini Rev Med Chem; 2012 Aug; 12(9):817-30. PubMed ID: 22681252
[TBL] [Abstract][Full Text] [Related]
30. G-protein-coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives.
Sebastiani G; Ceccarelli E; Castagna MG; Dotta F
Best Pract Res Clin Endocrinol Metab; 2018 Apr; 32(2):201-213. PubMed ID: 29678286
[TBL] [Abstract][Full Text] [Related]
31. [Operational models of allosteric modulation of G protein-coupled receptors].
Gong H; Zhang S; Ye RD
Yao Xue Xue Bao; 2016 Dec; 51(12):1829-37. PubMed ID: 29908534
[TBL] [Abstract][Full Text] [Related]
32. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox.
Langmead CJ; Christopoulos A
Trends Pharmacol Sci; 2006 Sep; 27(9):475-81. PubMed ID: 16889837
[TBL] [Abstract][Full Text] [Related]
33. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors.
Mohr K; Schmitz J; Schrage R; Tränkle C; Holzgrabe U
Angew Chem Int Ed Engl; 2013 Jan; 52(2):508-16. PubMed ID: 23225228
[TBL] [Abstract][Full Text] [Related]
34. Allosteric approaches to the targeting of G-protein-coupled receptors for novel drug discovery: a critical assessment.
Raddatz R; Schaffhauser H; Marino MJ
Biochem Pharmacol; 2007 Aug; 74(3):383-91. PubMed ID: 17572390
[TBL] [Abstract][Full Text] [Related]
35. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.
Keov P; Sexton PM; Christopoulos A
Neuropharmacology; 2011 Jan; 60(1):24-35. PubMed ID: 20637785
[TBL] [Abstract][Full Text] [Related]
36. Modulating receptor function through RAMPs: can they represent drug targets in themselves?
Sexton PM; Poyner DR; Simms J; Christopoulos A; Hay DL
Drug Discov Today; 2009 Apr; 14(7-8):413-9. PubMed ID: 19150656
[TBL] [Abstract][Full Text] [Related]
37. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities.
De Amici M; Dallanoce C; Holzgrabe U; Tränkle C; Mohr K
Med Res Rev; 2010 May; 30(3):463-549. PubMed ID: 19557759
[TBL] [Abstract][Full Text] [Related]
38. Natural Compounds as Guides for the Discovery of Drugs Targeting G-Protein-Coupled Receptors.
Serrano-Marín J; Reyes-Resina I; Martínez-Pinilla E; Navarro G; Franco R
Molecules; 2020 Oct; 25(21):. PubMed ID: 33143389
[TBL] [Abstract][Full Text] [Related]
39. Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases.
Coughlin Q; Hopper AT; Blanco MJ; Tirunagaru V; Robichaud AJ; Doller D
J Med Chem; 2019 Jul; 62(13):5979-6002. PubMed ID: 30721063
[TBL] [Abstract][Full Text] [Related]
40. Ligand properties and behaviours in an allosteric age.
Langmead CJ
Trends Pharmacol Sci; 2012 Dec; 33(12):621-2. PubMed ID: 23021944
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
